Menu
Search
|

Menu

Close
X

Amicus Therapeutics Inc FOLD.OQ (NASDAQ Stock Exchange Global Market)

12.69 USD
+0.11 (+0.87%)
As of Jul 17
Previous Close 12.58
Open 12.57
Volume 598,352
3m Avg Volume 828,129
Today’s High 12.82
Today’s Low 12.40
52 Week High 16.27
52 Week Low 8.28
Shares Outstanding (mil) 164.57
Market Capitalization (mil) 2,478.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
34
FY18
91
FY17
37
FY16
5
EPS (USD)
FY19
-0.563
FY18
-1.866
FY17
-1.848
FY16
-1.487
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
152.19
7.92
Price to Book (MRQ)
vs sector
8.09
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
59.64
14.56
LT Debt to Equity (MRQ)
vs sector
59.64
10.21
Return on Investment (TTM)
vs sector
-24.93
14.49
Return on Equity (TTM)
vs sector
-69.35
15.79

EXECUTIVE LEADERSHIP

John Crowley
Chairman of the Board and Chief Executive Officer, Since 2011
Salary: $637,640.00
Bonus: $445,710.00
Bradley Campbell
President, Chief Operating Officer, Director, Since 2018
Salary: $468,109.00
Bonus: $327,209.00
Daphne Quimi
Chief Financial Officer, Since 2019
Salary: $207,508.00
Bonus: $39,889.00
Simon Jordan
Senior Vice President - International, Since 2019
Salary: --
Bonus: --
Jill Weimer
Senior Vice President of Discovery Research and Gene Therapy Science, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Cedarbrook Dr
CRANBURY   NJ   08512-3618

Phone: +1609.6622000

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

SPONSORED STORIES